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Red blood cell transfusion in a
patient with anti-AnWj: a case
report
R.E. STOWERS, E.M. RICHA, J.R. STUBBS,AND S.B.MOORE
Anti-AnWj (Anton) has been associated with clinically significant
hemolytic transfusion reactions. More than 99 percent of studied
populations have RBCs that express the antigen. Reported here is
a patient with anti-AnWj who was transfused with antigen-positive
RBCs without adverse reaction. Immunohematology 2007;
23:55–58.
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The AnWj antigen is located in the ISBT 901 series
of high-incidence antigens. It has a more than 99
percent occurrence in all populations.1 As such, the
clinical significance of an anti-AnWj has to be
interpreted carefully as RBC units negative for this
antigen are extremely rare. Limited evidence exists to
help guide transfusion practice in patients with this
antibody; we describe a single case in which a patient
whose serum contained anti-AnWj was successfully
transfused with serologically incompatible RBCs
without an adverse reaction. The signs and symptoms
of an adverse reaction include fever or chills or both,
nausea or vomiting, pain (at infusion site or flank),
dyspnea, hypotension or tachycardia or both, renal
failure, disseminated intravascular coagulation, jaun-
dice, hemoglobinemia, hemoglobinuria, inadequate
increase in posttransfusion Hb, increase in bilirubin
(e.g., indirect bilirubin), increase in LDH,and decreased
haptoglobin.
Case Report
The subject was a 57-year-old Caucasian male (of
German, Irish, and French descent) with a history of
autoimmune hemolytic anemia (AIHA) that was
diagnosed at a different institution in March 2005 and
was treated with prednisone and azathioprine. He was
admitted on July 25, 2005, to the coronary care unit at
our institution with a 40-pound weight loss and
unstable angina. He was diagnosed with a myocardial
infarction, and he was found to be anemic with a Hb of
8.3 g/dL. Cardiac catheterization showed three-vessel
coronary artery disease with high-grade stenosis of the
mid left anterior descending coronary artery. During
hospitalization, the following complications occurred:
hyperglycemia—probably related to steroid therapy—
Aspergillus fumigatus infection of the lower lobe of
the right lung,and bronchial bleeding during bronchos-
copy. The bronchial hemorrhage was associated with a
drop in Hb to 7.2 g/dL;RBC transfusion was considered
to be clinically indicated owing to the patient’s
coronary artery disease (CAD), chest pain (rated at 5 of




The American Red Cross (ARC) North Central
Blood Services (St. Paul, MN) had identified an anti-
AnWj in this patient’s serum in March 2005. They
documented it as reactive by IAT in saline and albumin.
According to the ARC report, the serum of the patient
reacted weakly using PEG-IAT with all RBCs tested,
including those that were either AnWj– or Lu(a–b–)
and the patient’s own RBCs. This panagglutinin was
detectable only in PEG-IAT. The ARC testing excluded
antibodies to common blood group antigens by using
test RBCs that were negative for AnWj or were
Lu(a–b–) by using both saline-IAT and albumin-IAT. The
DAT was positive (ARC did not specify strength) with
anti-human IgG and negative with anti-human C3b,
C3d. The ARC performed an elution because of the
positive DAT with anti-IgG and the resulting eluate
reacted with all RBCs tested, including those that were
AnWj– or Lu(a–b–). The patient’s RBC phenotype
performed by the ARC before any transfusion was as
follows: group O, D+, C+E–c–, M+N+S–s+, P1–, K–k+
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Kp(b+), Fy(a–b+), Jk(a–b+), AnWj–; the ARC did not
provide the Lutheran phenotype of the patient. These
results were interpreted to indicate the presence of an
antibody to the high-prevalence antigen AnWj plus a
warm autoantibody. The immune stimulus for
developing the anti-AnWj was unknown.
In light of observed evidence of the association
with delayed hemolytic transfusion reactions,2 the ARC
(St. Paul,MN) recommendation was to transfuse AnWj–
RBCs (if available) or RBCs with the dominant Lu
(a–b–) phenotype encoded by In(Lu).
Current serologic investigation
The patient arrived at our institution on July 25,
2005, after receiving two units of phenotypically
similar [E–, K–, Lu(a–b–)] group O, D+ RBCs provided
by the ARC and infused at another institution. Three
additional group O, D+ RBC units were transferred to
our facility by the ARC. These latter three units were
phenotypically similar (E–, K–) but the units were
Lu(a–b+) and thus AnWj+. Units were negative for E
and K as a precaution.
It is known that Lu(a–b–) RBCs have poor
expression of the AnWj antigen.1 Therefore, reagent
RBCs negative for AnWj were used in conjunction with
Lu(a–b–) reagent RBCs to evaluate for the presence of
antibodies to other major blood group antigens.
Testing in the immediate spin phase using the patient’s
plasma (collected in EDTA) revealed no reactivity with
reagent RBCs and 1+ reactivity against the autologous
RBCs. Testing was then carried into the PEG-IAT phase,
which showed 2+ and 3+ reactivity with AnWj+ and
Lu(a–b+) RBCs, respectively, w+ reactivity with AnWj–
and Lu(a–b–) RBCs, and 3+ reactivity with autologous
RBCs. A DAT showed 2+ reactivity using monoclonal
anti-human IgG (Ortho-Clinical Diagnostics, Raritan,
NJ) and was negative when tested with anti-human
C3b, C3d (Ortho-Clinical Diagnostics). Using the acid/
EDTA method, an elution was performed. The eluate
showed no reactivity at PEG-IAT against the same
antibody identification panel of RBCs described earlier.
Although our eluate results were puzzling, the rest of
our results were consistent with those reported by the
ARC in St. Paul when testing in PEG-IAT.
The rarity of the antibody also presents problems
when trying to locate antisera for typing the patient’s
RBCs. The AnWj typing sera at our institution failed to
react with the control RBCs, and we were unable to
locate additional antisera from outside sources. A
phenotype was performed for the common blood
group antigens, and, where indicated, the patient’s
RBCs were treated with acid/EDTA to remove antibody
that could interfere with antigen typing. The
phenotype performed in our facility was in agreement
with the ARC with the following additional antigen
typings: e+, CW+, Le(a–b+).
It was concluded through RBC antibody identifi-
cation testing and antigen typing that the patient
lacked alloantibodies to the major blood group
antigens, and it was inferred through testing performed
at our facility and the ARC that the patient had made
anti-AnWj. As previously mentioned, we could not
confirm the AnWj because of a lack of antisera, but the
ARC typed the patient’s RBCs and determined that they
were AnWj–. Autoanti-AnWj has been reported as a
result of transient suppression of the AnWj antigen,and
therefore we could not definitively rule out that
possibility.1 Testing in LISS decreased the panreactive
autoantibody’s strength to nonreactive macroscopi-
cally. An allogeneic adsorption was performed on the
patient’s serum using intact RBCs in an attempt to
remove the anti-AnWj to rule out all antibodies to
common blood group antigens using our test
methodology of choice, PEG-IAT. The adsorption was
performed on a phenotypically similar (matched for
antigens as described earlier—except AnWj) RBC
aliquot. The allogeneic adsorption was successful, and
there was no evidence of alloantibodies against any of
the major blood group antigens using PEG-IAT. Left
behind in the absorbate was an autoanti-e. We can
speculate that a warm autoantibody with specificity
other than anti-e exists, as well as one with anti-e
specificity.
The clinical service was made aware of the diffi-
culty in obtaining serologically compatible, antigen-
negative RBC units. Based on assessment of clinical
need by the patient’s service, an order for one unit of
RBCs was received. A unit known to be Lu(a–b–) was
crossmatched. This unit was serologically incompatible
(2+) using our routine PEG-IAT methodology,
presumably because of the warm autoantibody (as it
reacted 2+) but was compatible using LISS-IAT. This
unit was transfused without clinically evident
complications. Samples from the patient’s available
siblings (a total of four) were also crossmatched with
the patient’s plasma and were found to be
incompatible using both PEG-IAT and LISS-IAT
methods. RBC antigen typing was not performed on
the samples from the patient’s siblings as a result of this
incompatibility.
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Requests for Lu(a–b–) RBC units could not be filled
through the American Rare Donor Program (ARDP).
Because of this, it was considered necessary to assess
the likely clinical significance of the patient’s anti-
AnWj. A sample of the patient’s serum was sent to the
National Reference Laboratory for Blood Group
Serology of the ARC for performance of a monocyte
monolayer assay (MMA). Concurrently, an in vivo
radiolabeled (In-111) RBC survival study was
performed at our institution.
The MMA is an in vitro diagnostic evaluation of the
hemolytic potential of an antibody. It has been shown
previously through multiple studies to be a predictor of
RBC antibody clinical significance.3–5 It was performed
using group O AnWj– RBCs and group O AnWj+ RBCs.
Pooled monocytes from two normal blood donors
were used. The AnWj+ RBCs reacted strongly positive
by DAT after incubation with the patient’s serum.
AnWj– RBCs were negative by the DAT after incubation
with the patient’s serum. The percentages of reactive
monocytes, after incubation with the patient’s serum,
with and without fresh complement, were 19.0 per-
cent and 37.5 percent, respectively, with AnWj+ RBCs.
AnWj– RBCs, after incubation with the patient’s serum,
with and without fresh complement, displayed 0.5
percent and 0.3 percent of reactive monocytes, respec-
tively. Between 0 percent and 3 percent of reactive
monocytes is considered within the normal range.
Values above this range suggest that the antibody in
question may cause accelerated clearance of antigen-
positive RBCs.Again, the ARC recommendation was to
transfuse AnWj– RBCs.
In the radiolabeled survival study,6,7 an intravenous
infusion of 10 mL of indium 111-labeled Lu(a–b+) RBCs
(2+ crossmatch incompatible at PEG-IAT and w+ cross-
match incompatible at LISS-IAT) was administered, and
samples were obtained at specified intervals to deter-
mine the percentage of radiolabeled RBCs persisting in
the circulation. The intervals were 3 hours, 20 hours,
47 hours,and 70 hours after infusion. The results at the
specified intervals were 95 percent, 87 percent, 81
percent, and 80 percent, respectively. Data from this
particular test suggested that RBCs of this phenotype
were unlikely to undergo a clinically relevant degree of
hemolysis within 3 days of transfusion.
Clinical outcome
Because of clinical necessity and despite the
conflicting predictive test results, a decision was made
to transfuse two available units of Lu(a–b–) RBCs that
were 1+ and 2+ crossmatch incompatible in PEG-IAT
phase but compatible in LISS-IAT phase of testing. The
transfusions were without any clinically apparent
adverse outcomes, and 2 days later the patient’s Hb
level had risen from 7.2 g/dL to 8.6 g/dL.Subsequent to
that transfusion, no more Lu(a–b–) units were available
at our institution, and the ARDP was unable to supply
additional units. The patient required further trans-
fusion and was transfused two (1+ incompatible at
PEG-IAT and compatible at LISS-IAT) units of Lu(a–b+)
RBCs, again without any clinical adverse reaction. Our
transfusion service recommended premedication with
IVIG (1 g/kg) and IV hydrocortisone to reduce the
possibility of an acute hemolytic reaction and its
clinical effects. The patient’s Hb increased from 8.1
g/dL before transfusion to 11.2 g/dL after transfusion.
Owing to the nature of his warm AIHA, anti-AnWj, and
compounding myocardial infarction and CAD, the
patient’s clinical service limited blood loss from
laboratory testing and phlebotomy. Because of this,
there were few biochemical markers for hemolysis
ordered. Results from those that were are summarized
in Figure 1.
At another hospital, the patient later underwent
coronary artery bypass graft surgery. He presented to
our institution 10 months later, in September 2006,
with gastrointestinal bleeding associated with the use
of aspirin and other nonsteroidal anti-inflammatory
medications. His Hb level on admission was 6.1 g/dL
and dropped to 5.1 g/dL the next day. In addition to
the anti-AnWj, an anti-Fya was found, further compli-
cating the patient’s serologic workup. No serologically
compatible units or units that were Lu(a–b–), Fy(a–)
were available. Two units of Lu(a–b+), Fy(a–) RBCs
were transfused (reactions were 2+ incompatible at
Fig. 1. Results of hemoglobin and bilirubin measurements for the
patient during his hospital stay. RBC transfusions (and Lutheran
phenotype) are indicated.
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PEG-IAT and 1+ incompatible at LISS-IAT) without
adverse reaction and his posttransfusion Hb stabilized
at 6.1 g/dL.
Discussion
Although anti-AnWj has been reported to cause
significant clinical hemolysis, there is clearly
insufficient experience to reliably predict its potential
for hemolysis in any particular case.8 The MMA and in
vivo RBC survival testing in our case gave conflicting
information, and the RBC survival study seemed to
more accurately predict the clinical result in this case.
It should be noted that, although it is unlikely, the MMA
could have been influenced by an antibody to an
unidentified low-prevalence antigen. Although RBC
units negative for AnWj are virtually impossible to
locate in the general population, it is slightly less
difficult to find Lu(a–b–) units. The patient’s clinical
condition led to a decision that RBC transfusion was
necessary despite the inability to locate AnWj– or
Lu(a–b–) RBC units for him. Based on the objective
evidence provided by the in vivo survival study, we
deemed Lu(a–b+) RBC units, in spite of serologic
incompatibility, to be a relatively safe choice for
transfusion. The patient suffered no apparent adverse
clinical events after transfusion. One may wish to
consider that this occurred because the initially
reported alloanti-AnWj may, in fact, have been an
autoanti-AnWj. However, this is only one case, and it is
certainly possible that quite different results might be
found in other cases. Similarly, caution should be taken
with patients who have antibodies to high-prevalence
antigens whose clinical significance is unknown. This
case report should not be applied generally to all
antibodies to high-prevalence antigens.
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